JB170

3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase.
(Pink: Aurora A ligand (HY-10971); Blue: Cereblon ligand (HY-103597); Black: linker).

For research use only. We do not sell to patients.

  • Purity: 98.70%
  • CAS No.: 2705844-82-0
  • Formula: C48H44ClFN8O11
  • Molecular Weight:963.36
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00